Ethnicity and antipsychotic response

Annals of Pharmacotherapy

Volumn 31, Issue 11, 1997, Pages 1360-1369

  Frackiewicz, Edyta J ^a   Sramek, John J ^a   Herrera, John M ^b   Kurtz, Neil M ^c   Cutler, Neal R ^a  

^a CALIFORNIA CLINICAL TRIALS   (United States)

^b Drug Treatment Services   (United States)

^c Worldwide Clinical Trials   (United States)

Author keywords

Antipsychotics; Ethnicity; Race

Indexed keywords

CLOZAPINE; CYTOCHROME P450; DOPAMINE 4 RECEPTOR; FLUPHENAZINE; HALOPERIDOL; NEUROLEPTIC AGENT;

AGRANULOCYTOSIS; ALCOHOL CONSUMPTION; ASIAN; CAUCASIAN; CHRONICITY; CLINICAL TRIAL; DIET; DRUG BLOOD LEVEL; ENVIRONMENTAL FACTOR; ETHNIC DIFFERENCE; EXTRAPYRAMIDAL SYMPTOM; HUMAN; NEGRO; OBSERVER VARIATION; PHARMACOGENETICS; PRESCRIPTION; PRIORITY JOURNAL; PSYCHOSIS; RACE DIFFERENCE; REVIEW; SMOKING; TARDIVE DYSKINESIA;

EID: 0030690073     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1177/106002809703101114     Document Type: Review

References (109)

1. Smith MW, Mendoza R. Ethnicity and pharmacogenetics. Mt Sinai J Med 1996;63:285-90.
2. Sramek JJ, Pi EH. Ethnicity and antidepressant response. Mt Sinai J Med 1996;63:320-5.
3. Chiu H, Lee S, Leung CM, Wing YK. Antipsychotic prescription for Chinese schizophrenics in Hong Kong. Aust NZJ Psychiatry 1992;26: 262-4.
4. Collazo J, Tam R, Sramek JJ, Herrera J. Neuroleptic dosing in Hispanic and Asian inpatients with schizophrenia. Mt Sinai J Med 1996;63:310-3.
5. Lin KM, Finder E. Antipsychotic dosage for Asians. Am J Psychiatry 1983;140:490-1.
6. Lin KM, Poland RE, Lau JK, Rubin RT. Haloperidol and prolactin concentrations in Asians and Caucasians. J Clin Psychopharmacol 1988;8: 195-201.
7. Lin KM, Poland RE, Nuccio I, Matsuda K, Hathuc N, Su TP, et al. A longitudinal assessment of haloperidol doses and serum concentrations in Asian and Caucasian schizophrenic patients. Am J Psychiatry 1989; 146:1307-11.
8. Midha KK, Hawes E, Hubbard J, Korchinski ED, McKay G. Variation in the single dose pharmacokinetics of fluphenazine in psychiatric patients. Psychopharmacology 1988;96:206-11.
9. Potkin SG, Shen Y, Pardes H, Phelps BH, Zhou D, Shu L, et al. Haloperidol concentrations elevated in Chinese patients. Psychiatry Res 1984;12: 167-72.
10. Ruiz S, Chu P, Sramek JJ, Herrera J. Neuroleptic dosing in Asian and Hispanic outpatients with schizophrenia. Mt Sinai J Med 1996;63:306-9.
11. Sramek JJ, Sayles MA, Simpson GM. Antipsychotic dosage for Asians: a failure to replicate. Am J Psychiatry 1986;143:535-6.
12. Jefferson JW, Greist JH. Brussels sprouts and psychopharmacology (understanding the cytochrome P450 enzyme system). In: Jefferson JW, Greist JH, eds. Annual of Drug Therapy. Vol. 3. Philadelphia: WB Saunders, 1996:2-22.
13. Nemeroff CB, Devane CL, Pollock BG. Newer antidepressants and the cytochrome P-450 system. Am J Psychiatry 1996;153:311-20.
14. Lin KM, Anderson D, Poland RE. Ethnicity and psychopharmacology: bridging the gap. Psychiatr Clin North Am 1995;18:635-47.
15. Eichelbaum M, Gross AS. The genetic polymorphism of debrisoquine/ sparteine metabolism: clinical aspects. Pharmacol Ther 1990;46:377-94.
16. Siddoway LA, Thompson KA, McCallister CB, Wang T, Wilkinson GR, Roen DM, et al. Polymorphism of propafenone metabolism and disposition in man: clinical and pharmacokinetic consequences. Circulation 1987;75:785-91.
17. Kroemer HK, Eichelbaum M. "It's the genes, stupid." Molecular basis and clinical consequences of genetic cytochrome P450 2D6 polymorphism. Life Sci 1995;56:2285-99.
18. Wedlund PJ, Aslanian WS, McAllister CB, Wilkinson GR, Branch RA. Mephenytoin hydroxylation deficiency in Caucasians: frequency of a new oxidative drug metabolism polymorphism. Clin Pharmacol Ther 1984;36:773-80.
19. Mahgoub A, Idle JR, Dring LG, Gancaster R, Smithy RL. Polymorphic hydroxylation of debrisoquine in man. Lancet 1977;2:584-6.
20. Inaba T, Junma M, Nakano M, Kalow W. Mephenytoin and sparteine pharmacogenetics in Canadian Caucasians. Clin Pharmacol Ther 1984; 36:670-6.
21. Lou YC, Ying L, Bertilsson L, Sjoqvist F. Low frequency of slow debrisoquine hydroxylation in a native Chinese population. Lancet 1987;2: 852-3.
22. Horai Y, Nakano M, Ishizaki T, Ishikawa K, Zhou HH, Zhou BJ, et al. Metoprolol and mephenytoin oxidation polymorphisms in Far Eastern Oriental subjects: Japanese versus mainland Chinese. Clin Pharmacol Ther 1989;46:198-207.
23. Nakamura K, Goto F, Ray WA, McAllister CB, Jacqz E. Inter-ethnic differences in genetic polymorphism of debrisoquin and mephenytoin hydroxylation between Japanese and Caucasian populations. Clin Pharmacol Ther 1985;38:402-8.
24. Woolhouse NM, Andoh B, Mahgoub A, Sloan TP, Idle JR, Smith RL. Debrisoquin hydroxylation polymorphism among Ghanaians and Caucasians. Clin Pharmacol Ther 1979;26:584-91.
25. Woolhouse N, Eichelbaum M, Oates NS, Idle JR, Smith RL. Dissociation of coregulatory control of debrisoquin/phenformin and sparteine oxidation in Ghanaians. Clin Pharmacol Ther 1985;37:512-21.
26. Mbanefo D, Babbunkmi EA, Mahgoub A, Sloan TP, Idle JR, Smith RL, et al. A study of the debrisoquine hydroxylation polymorphism in a Nigerian population. Xenobiotica 1980;10:811-8.
27. Iyun AO, Lennard MS, Tucker GT, Wood HJF. Metoprolol and debrisoquin metabolism in Nigerians: lack of evidence for polymorphic oxidation. Clin Pharmacol Ther 1986;40:387-94.
28. Sommers K, Moncrieff J, Avenant J. Polymorphism of the 4-hydroxylation of debrisoquin in Bushmen of Southern Africa. Hum Toxicol 1988; 7:273-6.
29. Reling MV, Cherrie J, Schell MJ, Petros WP, Meyer WH, Evans WE. Lower prevalence of the debrisoquin oxidative poor metabolizer phenotype in African-American versus Caucasian subjects. Clin Pharmacol Ther 1991;50:308-13.
30. Marinac JS, Foxworth JW, Willsie SK. Dextromethorphan polymorphic hepatic oxidation (CYP2D6) in healthy Black American adult subjects. Ther Drug Monit 1995;17:120-4.
31. Ramirez F. Ethnicity and psychopharmacology in Latin America. Mt Sinai J Med 1996;63:330-1.
32. Johansson I, Yue QY, Dahl ML, Heim M, Säwe J, Bertilsson L, et al. Genetic analysis of the interethnic differences between Chinese and Caucasians in the polymorphism of debrisoquine and codeine. Eur J Clin Pharmacol 1991;40:553-6.
33. Conney AH, Pantuck EJ, Hsiao KC, Kuntzman R, Alvares AP, Kappas A. Regulation of drug metabolism in man by environmental chemicals and diet. Fed Proc 1977;36:1647-52.
34. Jusko WJ. Role of tobacco smoking in pharmacokinetics. J Pharmacokinet Biopharm 1978;6:7-39.
35. Jann MW, Saklad SR, Ereshefsky L, Richards AL, Harrington CA, Davis CM. Effects of smoking on haloperidol and reduced haloperidol plasma concentrations and haloperidol clearance. Psychopharmacology 1986;90:468-70.
36. Pantuck EJ, Pantuck CB, Anderson K, Conney AH, Kappas A, Nutley N. Cigarette smoking and chlorpromazine disposition and action. Clin Pharmacol Ther 1982;31:533-8.
37. Stimmel GL, Falloon IR. Chlorpromazine plasma levels, adverse effects, and tobacco smoking: case report. J Clin Psychiatry 1983;44:420-2.
38. Sramek JJ, Herrera J, Swati R, Parent M, Hudgins R, Costa J, et al. An analysis of steady state chlorpromazine plasma levels in the clinical setting. J Clin Psychopharmacol 1987;7:117-8.
39. Ereshefsky L, Jann MW, Saklad SR, Davis CM, Richards AL, Burch NR. Effects of smoking on fluphenazine clearance in psychiatric inpatients. Biol Psychiatry 1985;20:329-32.
40. Hymowitz N, Corle D, Royce J, Hartwell T, Corbett K, Orlandi M, et al. Smokers' baseline characteristics in the COMMIT trial. Prev Med 1995; 24:503-8.
41. Rogers RG, Nam CB, Hummer RA. Demographic and socioeconomic links to cigarette smoking. Soc Biol 1995;42:1-21.
42. Dollery CT, Fraser HS, Mucklow JC, Bulpitt CJ. Contribution of environmental factors to variability in human drug metabolism. Drug Metab Rev 1979;9:207-20.
43. Naranjo CA, Bremner KE. Behavioral correlates of alcohol intoxication. Addiction 1993;88:25-35.
44. Lane EA, Guthrie S, Linnoila M. Effects of ethanol on drugs and metabolite pharmacokinetics. Clin Pharmacokinet 1985;10:228-47.
45. Muhoberac BB, Roberts RK, Hoympa AM Jr, Schenker S. Mechanism(s) of ethanol-drug interaction. Alcohol Clin Exp Res 1984;8:583-93.
46. Meir PJ. Alcohol, alcoholism and drugs. Schweiz Med Wochenschr 1985;115:1792-803.
47. O'Hare T. Differences in Asian and white drinking: consumption level, drinking contexts, and expectancies. Addict Behav 1995;20:261-6.
48. Higuchi S, Parrish KM, Dufour MC, Towle LH, Harford TC. Relationship between age and drinking patterns and drinking problems among Japanese, Japanese-Americans, and Caucasians. Alcohol Clin Exp Res 1994;18:305-10.
49. Li HZ, Rosenblood L. Exploring factors influencing alcohol consumption patterns among Chinese and Caucasians. J Stud Alcohol 1994;55: 427-33.
50. Cheung YW. Beyond liver and culture: a review of theories and research in drinking among Chinese in North America. Int J Addict 1993;28: 1497-513.
51. Wolff PH. Ethnic differences in alcohol sensitivity. Science 1972;175: 449-50.
52. Ewing JA, Rouse BA, Perllizzari ED. Alcohol sensitivity and ethnic background. Am J Psychiatry 1974;131:206-10.
53. Ewing JA, Rouse A, Aderhold RM. Studies of the mechanism of Oriental hypersensitivity to alcohol. Curr Alcohol 1979;5:45-52.
54. Seto A, Tricomi S, Goodwin DW, Kolodney R, Sullivan T. Biochemical correlates of ethanol-induced flushing in Orientals. J Stud Alcohol 1978; 39:1-11.
55. Wall TL, Ehlers CL. Acute effects of alcohol on P300 in Asians with different ALDH2 genotypes. Alcohol Clin Exp Res 1995;19:617-22.
56. Michnovicz JJ, Bradlow HL. Altered estrogen metabolism and excretion in humans following consumption of indole-3-carbinol. Nutr Cancer 1991;16:59-66.
57. Pantuck EJ, Pantuck CB, Garlan WA. Stimulatory effect of brussels sprouts and cabbage on human drug metabolism. Clin Pharmacol Ther 1979;25:88-95.
58. Anderson KE, Kappas A. Dietary regulation of cytochrome P-450. Annu Rev Nutr 1991;11:141-67.
59. Kappas A, Anderson KE, Conney AH, Alvares AP. Influence of dietary protein and carbohydrate on antipyrine and theophylline metabolism in man. Clin Pharmacol Ther 1976;20:643-53.
60. Kalow W. Ethnic differences in drug metabolism. Clin Pharmacokinet 1982;7:373-400.
61. Patterson BH, Harlan LC, Block G, Kahle L. Food choices of whites, blacks and Hispanics: data from the 1987 National Health Interview Survey. Nutr Cancer 1995;23:105-19.
62. Otero-Sabogal R, Sabogal F, Perez-Stable EJ, Hiatt RA. Dietary practices, alcohol consumption, and smoking behavior: ethnic, sex, and acculturation differences. J Natl Cancer Inst Monogr 1995;18:73-82.
63. Guendelman S, Abrams B. Dietary intake among Mexican-American women: generation differences and a comparison with white non-Hispanic women. Am J Public Health 1995;85:20-5.
64. Winkleby MA, Albright CL, Howard-Pitney B, Lin J, Fortmann SP. Hispanic/white differences in dietary fat intake among low educated adults and children. Prev Med 1994;23:465-73.
65. Liu GT. Effects of some compounds isolated from Chinese medicinal herbs in hepatic microsomal cytochrome P-450 and their potential biological consequences. Drug Metab Rev 1991;23:439-65.
66. Luscombe DK. Factors influencing plasma drug concentrations. J Int Med Res 1977;5(suppl 1):S82-97.
67. Lawson GM. Monitoring of serum haloperidol. Mayo Clin Proc 1994; 69:189-90.
68. Anderson KE. Influences of diet and nutrition on clinical pharmacokinetics. Clin Pharmacokinet 1988;14:325-46.
69. O'Mahony MS, Woodhouse KW. Age, environmental factors and drug metabolism. Pharmacol Ther 1994;61:279-87.
70. Mendoza R, Smith MW, Poland RE, Lin KM, Strickland TL. Ethnic psychopharmacology: the Hispanic and Native American perspective. Psychopharmacol Bull 1991;27:449-61.
71. Crabtree BL, Jann MW, Pitts WM. Alpha-1 acid glycoprotein levels in patients with schizophrenia: effect of treatment with haloperidol (abstract). Biol Psychiatry 1991;29:70A.
72. Zhou HH, Adedoyin A, Wilkinson G. Differences in plasma binding of drugs between Caucasians and Chinese subjects. Clin Pharmacol Ther 1990;48:10-7.
73. Lin KM, Poland RE, Lesser IM. Ethnicity and psychopharmacology. Cult Med Psychiatry 1986;10:151-65.
74. Sramek JJ, Simpson GM. Antipsychotic drugs in schizophrenia. In: Cutler NR, Sramek JJ, Narang PK, eds. Pharmacodynamics and drug development. West Sussex, England: John Wiley & Sons Ltd., 1994:181-200.
75. Seeman P, Ulpian C, Chouinard G, Van Tol HHM, Dwosh H, Lieberman JA. Dopamine D4 receptor variant, D4GLYCINE194, in Africans, but not in Caucasians: no association with schizophrenia. Am J Med Genet 1994;54:384-90.
76. Garver DL, Griffith J, Hirschowitz J. Minimum effective dose of haloperidol in treatment of psychoses (abstract). Biol Psychiatry 1994;35: 667.
77. Janicak PG, Javaid JI, Sharma RP, Leach A, Dowd S, Blake L, et al. Random assignment to three haloperidol plasma concentrations for acute psychosis (abstract). Biol Psychiatry 1994;35:366.
78. Neborsky R, Janowsky D, Munson E, Depry D. Rapid treatment of acute psychotic symptoms with high and low dose haloperidol. Arch Gen Psychiatry 1981;38:195-9.
79. 2 receptor occupancy with low-dose haloperidol treatment: a PET study. Am J Psychiatry 1996;153:948-50.
80. Baldessarini RJ, Katz B, Cotton P. Dissimilar dosing with high potency and low potency antipsychotics. Am J Psychiatry 1984;141:748-52.
81. Binder RL, Kazamatsuri H, Nishimura T, McNeil DE. Tardive dyskinesia and antipsychotic-induced parkinsonism in Japan. Am J Psychiatry 1987;144:1494-6.
82. Adebimpe VR. Overview: white norms and psychiatric diagnosis of black patients. Am J Psychiatry 1981;138:279-85.
83. Mukherjee S, Shukla S, Woodle J, Rosen AM, Olarte S. Misdiagnosis of schizophrenia in bipolar patients: a multiethnic comparison. Am J Psychiatry 1983;140:1571-4.
84. Glazer WM, Morgenstern H, Doucette J. Race and tardive dyskinesia among outpatients at a CMHC. Hosp Community Psychiatry 1994;45: 38-42.
85. Strakowski SM, Lonczak HS, Sax KW, West SA. The effects of race on diagnosis and disposition from a psychiatric emergency service. J Clin Psychiatry 1995;56:101-7.
86. Segal SP, Bola JR, Watson MA. Race, quality of care, and antipsychotic prescribing practices in psychiatric emergency services. Psychiatr Serv 1996;47:282-6.
87. Lawson WB, Yesavage JA, Werner PD. Race, violence, and psychopathology. J Clin Psychiatry 1984;45:294-7.
88. Adams GL, Dworkin RJ, Rosenberg SD. Diagnosis and pharmacotherapy issues in the care of Hispanics in the public sector. Am J Psychiatry 1984;141:970-4.
89. Hough RL, Landsverk JA, Karno M, Burman MA, Timbers DM, Escobar JI. Utilization of health and mental health services by Los Angeles Mexican-American and non-Hispanic whites. Arch Gen Psychiatry 1987;44:702-9.
90. Sue S, Fujino DC, Hu LT, Takeuchi DT, Zane NW. Community mental health services for ethnic minority groups: a test of the cultural responsiveness hypothesis. J Consult Clin Psychol 1991;59:533-40.
91. Miranda J, Azocar F, Organista KC, Munoz RF, Lieberman A. Recruiting and retaining low-income Latinos in psychotherapy research. J Consult Clin Psychol 1996;64:868-74.
92. Binder RL, Levy R. Extrapyramidal reactions in Asians. Am J Psychiatry 1981;138:1243-4.
93. Chiu H, Shum P, Lau J, Lam L, Lee S. Prevalence of tardive dyskinesia, and respiratory dyskinesia among Chinese psychiatric patients in Hong Kong. Am J Psychiatry 1992;149:1081-5.
94. Lieberman JA, Yunis J, Egea E, Canoso RT, Kane JM, Yunis EJ. HLA-B38, DR4, DQw3 and clozapine-induced agranulocytosis in Jewish patients with schizophrenia. Arch Gen Psychiatry 1990;47:945-8.
95. Sramek JJ, Roy S, Ahrens T, Pinanong P, Cutler NR, Pi E. Prevalence of tardive dyskinesia among three ethnic groups of chronic psychiatric patients. Hosp Community Psychiatry 1991;42:590-2.
96. Yunis JJ, Lieberman J, Yunis EJ. Major histocompatibility complex associations with clozapine-induced agranulocytosis. Drug Saf 1992;7:7-9.
97. Svensson CK. Representation of American blacks in clinical trials of new drugs. JAMA 1989;261:263-5.
98. Edwards L. Most major companies test medicines in women, monitor data for gender differences. New medicines in development for women (1991 survey). Washington, DC: Pharmaceutical Manufacturers of America, 1991:27-8.
99. Lewis-Hall F. Gender differences in psychotropic medications. Mt Sinai J Med 1996;63:326-9.
100. Chouinard G, Annabele L. Pimozide in the treatment of newly schizophrenic patients. Psychopharmacology 1982;76:13-9.
101. Simpson GM, Yakalam KG, Levinson DF, Stephanos J, Sing Lo EE, Cooper TB. Single dose pharmacokinetics of fluphenazine after fluphenazine decanoate administration. J Clin Psychopharmacol 1990;10: 417-21.
102. Ereshefsky L, Saklad SR, Watanabe MD, Davis CM, Jann MW. Thiothixene pharmacokinetic interactions: a study of hepatic enzyme inducers, clearance inhibitors, and demographic variables. J Clin Psychopharmacol 1991;11:269-301.
103. Smith JM, Dunn DD. Sex differences in the prevalence of severe tardive dyskinesia. Am J Psychiatry 1979;136:1080-2.
104. Chouinard G, Annabele L, Ross-Chouinard A, Nestoros JN. Factors related to tardive dyskinesia. Am J Psychiatry 1979;136:79-83.
105. Edeki TI. Clinical importance of genetic polymorphism of drug oxidation. Mt Sinai J Med 1996;63:291-300.
106. Jann MW, Ereshefsky L, Saklad SR, Seidel DL, Davis CM, Burch NR, et al. Effects of carbamazepine on plasma haloperidol concentrations. J Clin Psychopharmacol 1985;5:106-9.
107. Llerena A, Herraiz AG, Cobaleda J, Johansson I, Dahl ML. Debrisoquin and mephenytoin hydroxylation phenotypes and CYP2D6 genotype in patients treated with neuroleptic and antidepressant agents. Clin Pharmacol Ther 1993;54:606-11.
108. Jamerson K, DeQuattro V. The impact of ethnicity on response to antihypertensive therapy. Am J Med 1996;101(suppl 3A):22S-32S.
109. Edeki TI, Brase DA. Phenytoin disposition and toxicity: role of pharmacogenetic and interethnic factors. Drug Metab Rev 1995;27:449-69.